References
- SuraweeraAO’ByrneKJRichardDJCombination therapy with histone deacetylase inhibitors (HDACi) for the treatment of cancer: achieving the full therapeutic potential of HDACiFront Oncol201889229651407
- ChunPHistone deacetylase inhibitors in hematological malignancies and solid tumorsArch Pharm Res20153893394925653088
- GolabekKStrzelczykJKWiczkowskiAMichalskiMPotential use of histone deacetylase inhibitors in cancer therapyContem Oncol201519436440
- ImaiYMaruYTanakaJAction mechanisms of histone deacetylase inhibitors in the treatment of hematological malignanciesCancer Sci20161071543154927554046
- WapenaarHDekkerFJHistone acetyltransferases: challenges in targeting bi-substrate enzymesClin Epigenetics201685927231488
- GinsburgDSAnlembomTEWangJNuA4 links methylation of histone H3 lysines 4 and 36 to acetylation of histones H4 and H3J Biol Chem2014289326563267025301943
- SowaYOritaTHiranabe-MinamikawaSHistone deacetylase inhibitor activates the p21/WAF1/Cip1 gene promoter through the Sp1 sitesAnn N Y Acad Sci199988619519910667218
- SaundersAHuangXFidalgoMThe SIN3A/HDAC corepressor complex functionally cooperates with NANOG to promote pluripotencyCell Rep2017181713172628199843
- MoreauxJRemeTLeonardWGene expression-based prediction of myeloma cell sensitivity to histone deacetylase inhibitorsBr J Cancer201310967668523868005
- FandyTESrivastavaRKTrichostatin A sensitizes TRAIL-resistant myeloma cells by downregulation of the antiapoptotic Bcl-2 proteinsCancer Chemother Pharmacol20065847147716435155
- HellerGSchmidtWMZieglerBGenome-wide transcriptional response to 5-aza-2′-deoxycytidine and trichostatin A in multiple myeloma cellsCancer Res200868445418172295
- LiTLiYMJiaZQChenPMaKTZhouCYCarboxyl terminus of Nkx2.5 impairs its interaction with p300J Mol Biol200737097699217544441
- LiuZXuJHeJA critical role of autocrine sonic hedgehog signaling in human CD138+ myeloma cell survival and drug resistanceBlood20141242061207125049282
- EckschlagerTPlchJStiborovaMHrabetaJHistone deacetylase inhibitors as anticancer drugsInt J Mol Sci210718 pii:E1414
- TangYZhaoWChenYZhaoYGuWAcetylation is indispensable for p53 activationCell200813361262618485870
- JeongJWBaeMKAhnMYRegulation and destabilization of HIF-1alpha by ARD1-mediated acetylationCell2001111709720
- KramerOHZhuPOstendorffMThe histone deacetylase inhibitor valproic acid selectively induces proteasomal degradation of HDAC2EMBO J20132234113420
- StockhausenMTSjolundJManetopoulosCAxelsonHEffects of the histone deacetylase inhibitor valproic acid on Notch signalling in human neuroblastoma cellsBr J Cancer20059275175915685243
- OkCYSinghRRVegaFAberrant activation of the hedgehog signaling pathway in malignant hematological neoplasmsAm J Pathol201218021122056910
- CanettieriGDi MarcotullioLGrecoAHistone deacetylase and Cullin3-REN(KCTD11) ubiquitin ligase interplay regulates hedgehog signalling through Gli acetylationNat Cell Biol20101213214220081843
- MazzaDInfantePColichhiaVPCAF ubiquitin ligase activity inhibits hedgehog/Gli1 signaling in p53-dependent response to genotoxic stressCell Death Differ2013201688169724013724
- MieleEPoABegalliFBeta-arrestin1-mediated acetylation of Gli1 regulates hedgehog/Gli signaling and modulates self-renewal of SHH medulloblastoma cancer stem cellsBMC Cancer20171748828716052
- ConiSMancusoABDi MangoLSelective targeting of HDAC1/2 elicits anticancer effects through Gli1 acetylation in preclinical models of SHH medulloblastomaSci Rep201774407928276480